Arcturus Therapeutics 3Q Loss/Shr 26c >ARCT

Third-quarter revenue rose 7% year over year, while net loss narrowed as lower research and development costs—including reduced clinical-trial and manufacturing expenses for LUNAR-COVID and BARDA—more than offset lower grant revenue. Collaboration revenue benefited from the CSL agreement terminatio…